Cytek Biosciences: Hold Rating Amid Revenue Decline and Macroeconomic Uncertainties

Tejas Savant, an analyst from Morgan Stanley, maintained the Hold rating on Cytek Biosciences (CTKB – Research Report). The associated price target remains the same with $9.00.

Tejas Savant has given his Hold rating due to a combination of factors impacting Cytek Biosciences. The company’s recent financial performance showed a decline in product revenue, primarily due to a softer instrument market in the US and EMEA regions, as well as foreign exchange headwinds. These challenges resulted in fourth-quarter revenues that were in line with preliminary announcements but below market expectations.
Additionally, while service revenue showed growth, the overall outlook for 2025 remains clouded by uncertainties such as potential policy changes affecting NIH budgets, export controls, and tariffs. Despite an undemanding valuation, the limited upside potential in the current macroeconomic environment suggests a cautious approach, leading to the Hold rating until there is more clarity and improvement in these external factors.

Savant covers the Healthcare sector, focusing on stocks such as Stevanato Group, Charles River Labs, and Pacific Biosciences. According to TipRanks, Savant has an average return of -6.0% and a 37.35% success rate on recommended stocks.